10-Q: ENDRA Life Sciences Q1 2026 Financial Results

ENDRA Life Sciences reports a net loss of $1.3 million for Q1 2026 while facing Nasdaq delisting risks due to equity deficiencies.

Summary

• Reported a net loss of $1.31 million for the three months ended March 31, 2026, compared to a $1.04 million loss in the same period of 2025.
• Operating expenses totaled $2.17 million, driven by $776,410 in research and development and $1.39 million in general and administrative costs.
• Cash and cash equivalents decreased to $356,462 as of March 31, 2026, from $762,365 at year-end 2025.
• The company is currently evaluating strategic alternatives, including potential mergers, asset sales, or collaborations.
• Received a notice from Nasdaq regarding non-compliance with the minimum stockholders' equity requirement.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a distressed situation characterized by significant cash depletion, a going concern warning, and a pending Nasdaq delisting threat.

Positives

• Realized a $738,177 unrealized gain on the fair value of digital assets held in the treasury.
• Successfully raised $263,747 in net proceeds through common stock issuances during the quarter.
• Generated $450,000 in cash proceeds from the sale of digital intangible assets.

Negatives

• Reported a net loss of $1.31 million for the quarter.
• Cash balance dropped significantly to $356,462, raising substantial doubt about the company's ability to continue as a going concern.
• Operating expenses increased to $2.17 million from $1.47 million in the prior year period.
• Management identified a material weakness in internal controls due to insufficient accounting personnel.

Risks

• Substantial doubt regarding the company's ability to continue as a going concern due to limited cash and recurring losses.
• Risk of delisting from The Nasdaq Stock Market due to failure to meet minimum stockholders' equity requirements.
• Dependence on raising additional capital through equity or debt, which may cause significant dilution to existing shareholders.
• Uncertainty regarding the success of the TAEUS technology commercialization and regulatory approval timelines.
• Volatility associated with the company's digital asset treasury strategy.

Future Outlook

The company plans to continue development of its TAEUS technology and pursue FDA approval, though it has delayed certain development activities to conserve cash. Management is actively reviewing strategic alternatives to address liquidity needs and regain Nasdaq compliance.

Management Comments

• Management acknowledges that the company has not established an ongoing source of revenue sufficient to cover operating costs.
• The company intends to take all reasonable measures available to regain compliance under the Nasdaq Listing Rules.

Industry Context

StockSavvy.ai notes that ENDRA's pivot toward a digital asset treasury strategy is highly unconventional for a pre-revenue medical device company, reflecting extreme pressure to manage cash burn in a challenging capital-raising environment.

Comparison to Industry Standards

• Unlike established medical device firms with diversified revenue streams, ENDRA remains entirely dependent on external financing.
• The company's reliance on DeFi assets for treasury management is an outlier compared to standard corporate treasury practices in the biotech sector.

Corporate Governance

Related Party Transactions

• The company utilizes Impact Solutions for CFO and bookkeeping services, with payments totaling $44,571 for the quarter.

Stakeholder Impact

• Shareholders face significant dilution risk if the company raises capital through equity offerings.
• Employees face uncertainty due to potential restructuring and cost-cutting measures.
• Creditors and suppliers may face risks associated with the company's liquidity constraints.

Next Steps

• Attend a hearing before the Nasdaq Hearings Panel to appeal the delisting determination.
• Continue the evaluation of strategic alternatives to address the company's financial position.
• Seek additional capital to fund operations through 2026.

Key Dates

Recommendation

The combination of a going concern warning, Nasdaq delisting notice, and severe cash constraints makes this a high-risk investment with a high probability of further shareholder dilution or insolvency.

Keywords

ENDRA Life Sciences, TAEUS, Medical Technology, Liver Fat Measurement, Digital Asset Treasury, Nasdaq Delisting, Going Concern